Swiss Visio Glaucoma Research Center

The aim of the research department at the Lausanne Glaucoma Centre is to conduct cutting-edge research, enabling the development of pioneering and innovative techniques and treatments to better diagnose, treat and one day cure glaucoma.


With more than 50 scientific publications since 2018, the montchoisi glaucoma research centre has rapidly become one of the most active centres in Switzerland in this field.

eyeWatch

Invented in Lausanne at the EPFL, the eyeWatch is a microscopic drainage tube used in glaucoma surgery. Made from biocompatible materials, this innovative device uses a magnetic valve to control intraocular pressure. By adjusting the valve, the post-operative complications associated with some conventional surgeries can be reduced. The eyewatch is thus the first device in the world to enable glaucoma surgery to be tailored to individual needs. Almost three years after it was first installed by Dr Mermoud at the Clinique de Montchoisi in Lausanne, its use continues to grow, and international journals have already devoted several articles to it. The initial long-term results have caught the attention of specialists in the scientific community. At the end of 2019, the eyeWatch also received the CE mark (European conformity), enabling it to be marketed in Europe. This certification indicates that the health, safety and environmental protection standards comply with the European Economic Area. Clinique de Montchoisi has exclusive rights in Switzerland.

thumbnail
click overlay image

Find out more on how the eyeWatch works and how it can change the daily vision.

OCT FLEX

Thanks to donations from generous donors, the Swiss Glaucoma Research Foundation has been able to acquire the OCT FLEX imaging system, making Swiss Visio Montchoisi the 3rd centre in the world to be equipped with this revolutionary system. This equipment enables a completely new imaging technique to be performed: angiography of the aqueous humour. This examination, developed at UCLA in California, shows the channels through which intraocular fluid evacuates, and could in future enable glaucoma surgeons to target their operations more effectively by adapting them specifically to the pathology of each patient.

Eyemate-SC

In September 2019, Dr Mansouri became the first surgeon in Switzerland to implant an Eyemate-SC sensor, at Swiss Visio Montchoisi. This intraocular sensor is implanted in the patient's sclera during filtering surgery to treat glaucoma, and is then used to measure intraocular pressure remotely and continuously using a wireless reading device. With this new technology, patients can now measure their intraocular pressures alone, at home, and share all their measurements with their ophthalmologist at the click of a button.

Finally seeing clear

Feel the freedom of going through life without glasses or contact lenses and enjoy a clear perspective in every life situation.

Book your free laser consultation today and discover how you can start a new chapter in your life without visual aids.

See finally clear

INTEGRAL register

The INTEGRAL register will eventually bring together anonymous clinical data from hundreds of glaucoma patients. The aim of the longitudinal study (over 5 to 10 years) of their evolution, with or without treatment, is to identify the genetic and environmental risk factors linked to the development and progression of glaucoma. Ultimately, this study will enable us to give patients better advice on the risks associated with their disease and the choice of treatment best suited to them.

Swiss Visio Montchoisi

Swiss Visio Beau-Rivage

placeholder image

Glaucoma

PERG

PERG or «Pattern Electroretinogram» is a technique that studies the functioning of the optic nerve, which transmits visual information from the eye to the brain. Using electrodes placed on the forehead and eyelids, this device detects the electrical signals emitted by the nerve cells in the retina, making it possible to detect deficits in the cells most affected by glaucoma. Ultimately, this machine has the potential to detect glaucoma earlier. Our studies into its effectiveness are ongoing.

OCT-A

OCT angiography is a non-invasive technique for accurately visualising the deep and superficial vasculature of the retina and optic nerve. The latter is proving to be just as affected by glaucoma as the nerve fibres that were previously thought to be the only ones affected. This technology should therefore give us a better understanding of the causes of glaucoma, and enable us to diagnose certain cases more accurately.

TriggerFish

Invented in Lausanne, this «intelligent» contact lens measures intraocular pressure continuously over a 24-hour period. A major innovation in the field of glaucoma, it means that pressure control can no longer be estimated on the basis of a single moment in the surgery, but that a true overview of values can be obtained throughout the patient's daily life. A number of promising studies have already been published: the study of pressure variations over the course of a day could soon complement certain traditional examinations.